BioSpace News Archive

Biotricity Inc. (OTCQB:BTCY), a medical diagnostic and consumer healthcare technology company, announced today that it has completed required lab testing and is completing its 510(k) FDA filing for its latest potential product offering, Biotres. Biotres is a 3-lead patch product for ECG and arrhythmia monitoring for patients at risk for or being diagnosed with certain cardiac issues. Biotres can work as a Holter, Event Loop, and Extende

FibroGen, Inc. (NASDAQ: FGEN) today announced the retirement of K. Peony Yu, M.D., Chief Medical Officer, and appointment of Mark Eisner, M.D., M.P.H. in that role. Dr. Yu will continue as Chief Medical Officer through December 20, 2020, the roxadustat PDUFA date, and will remain with FibroGen through March 15, 2021 serving as Executive Advisor to the CEO to support the transition. Dr. Yu joined FibroGen in 2008 and has provided key leadership

New long-term safety, efficacy, and durability data for FINTEPLA® (fenfluramine) oral solution in Dravet syndrome Full results from Phase 3 study of FINTEPLA in Lennox-Gastaut syndrome New d ata from investigator-initiated stud y in CDKL5 Deficiency Disorder

BioLife Solutions, Inc. (NASDAQ: BLFS) (“BioLife” or the “Company”), a leading developer and supplier of a portfolio of class-defining bioproduction products and services for cell and gene therapies, today announced two new co-investments with innovation accelerator partner Casdin Capital.

Biovo Technologies Ltd. (“Biovo”) (WSE: AWM), a medical device company focused on devices for Critical Care and Operating Rooms, announced today it has signed exclusive distribution agreements for B-Care Oral Care in Australia , Br

Posters Accepted for Presentation at the 62nd American Society of Hematology (ASH) Annual Meeting

Zimmer Biomet Holdings, Inc., a global leader in musculoskeletal healthcare, officially launched the Zimmer Biomet Foundation.

Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced that patient dosing has begun in ACT-AD, a Phase 2 randomized, placebo-controlled study of ATH-1017 in patients with mild-to-moderate Alzheimer’s disease

BridgeBio Pharma, Inc. (NASDAQ: BBIO), a clinical-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines for patients with genetic diseases and cancers with clear genetic drivers, and affiliate QED Therapeutics today announced that the U.S. food and Drug Administration (FDA) has accepted their New Drug Application (NDA) for infigratinib,

Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced that it has named Peter P. Pfreundschuh as its new chief financial officer